The U.S. Patent & Trademark Office issued a pre-approval to Framingham medical researcher Arch Therapeutics for a broad range of projects, including one that has been pre-clinically proven to stop bleeding when applied directly to a wound, the company announced Tuesday.
The pre-approval — which the patent office calls the notice of allowance and serves as an intention of Arch eventually receiving its patent — applies to Arch’s present and proposed products, which contain peptides that self assemble into barrier structures on tissue to hinder or prevent the passage of body fluids. The technology actually came out of MIT in Cambridge and the University of Hong Kong and is exclusively licensed to Arch.
The first product in development is the AC5 Surgical Hemostatic Device, a clear liquid product that in pre-clinical trials has successfully stopped bleeding when applied to a wound. The first human trial of AC5 will take place in Europe and the company plans to file a CE Mark this summer, said Terrence W. Norchi, Arch president and CEO.
